Company Overview and News

TerraCom upgrades coal reserve and boosts life of Blair Athol mine

TerraCom Ltd (ASX:TER) has extended the life of the Blair Athol mine in Queensland by a year after upgrading thermal coal reserves.
Upvote Downvote

Aspire Mining increases exposure to near-term coal production

Aspire Mining (ASX:AKM) has entered into an agreement to facilitate the exercise of its option to increase its ownership to 100% from 50% in the Ekhgoviin Chuluu Joint Venture (ECJV).
Upvote Downvote

TerraCom to update on acquisition

TerraCom (ASX:TER) has been granted a trading halt by the ASX, pending an update on the Blair Athol acquisition. The halt will remain in place until the opening of trade on Wednesday 17th May 2017, or earlier if an announcement will be made to the market.
Upvote Downvote

TerraCom Ltd resource upgrade extends coal mine life 2 years

TerraCom Ltd (ASX:TER) has improved the coal resources at the Blair Athol Project near Clermont in central Queensland.
Upvote Downvote

TerraCom Ltd acquires Blair Athol Coal Mine in Queensland for $1

TerraCom Ltd (ASX:TER) will acquire the Blair Athol Coal Mine, one of Queensland’s oldest coking coal mines, from the Blair Athol Coal Joint Venture for the heady price of $1. TerraCom will also receive $80 million from the vendors to meet Blair Athol Coal Mine’s rehabilitation liability as determined by Queensland’s Department of Environment Heritage Protection in November 2015. The mine ceased production under its current management in late 2012 and has been on care and maintenance since then.
Upvote Downvote

TerraCom Ltd to reveal acquisition

TerraCom Ltd (ASX:TER) is preparing to outline details of an acquisition, with the ASX granting the company a trading halt to prepare. TerraCom also noted that the company is in the final stages of negotiations on a strategic opportunity in Queensland to acquire a mature mining operation which is currently on care and maintenance. The halt will remain in place until the opening of trade on Monday 4th July 2016, or earlier if an announcement is made to the market.
Upvote Downvote

Appendix 3B

Upvote Downvote

Debt Restructuring

Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN:, Inc Analysis and Research Report

2018-04-25 - Asif

Overview opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...